Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Anavex Life Sciences (NASDAQ: AVXL): Blarcamesine's Regulatory Path in Focus

Anavex is a clinical-stage biotechnology company listed on theNasdaqunder AVXL, developing oral small-molecule therapies for central-nervous-system disorders. Its lead candidate, blarcamesine (ANAVEX2-73), a sigma-1 receptor agonist, is being advanced for early Alzheimer's disease, with additional programs in Rett syndrome and Fragile X syndrome.

Nitish Kishor | 10 September 2026

Akebia Therapeutics (NASDAQ: AKBA): Vafseo's Growth Against Auryxia's Decline

Akebia Therapeutics is a biopharmaceutical company focused on kidney disease, listed on theNasdaqunder AKBA. Its commercial portfolio is anchored by Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia due to chronic kidney disease in adults on dialysis, alongside Auryxia, an established phosphate-binder product now …

Nitish Kishor | 10 September 2026

Upstream Bio (NASDAQ: UPB): Verekitug Moves Into Pivotal Phase 3 Testing

Upstream Bio is developing verekitug, a monoclonal antibody that blocks the receptor for thymic stromal lymphopoietin (TSLP), an upstream driver of inflammation implicated across respiratory disease. On September 1, 2026, the company announced pivotal Phase 3 development plans for verekitug in both severe asthma …

Nitish Kishor | 10 September 2026

Matinas BioPharma (NYSE American: MTNB): The Deal Reshaping the Company Into Clean Energy

Matinas BioPharma built its reputation on a lipid nanocrystal (LNC) delivery platform and its lead candidate MAT2203, an oral formulation of the antifungal amphotericin B aimed at serious invasive fungal infections. On July 13, 2026, the company changed course dramatically. It signed a definitive …

Nitish Kishor | 10 September 2026

Eagle Pharmaceuticals (OTC: EGRX): From Nasdaq Drugmaker to Distressed Micro-Cap

Eagle Pharmaceuticals historically built its portfolio around injectable and specialty hospital products, including established franchises in oncology support and critical-care medicines, alongside efforts to broaden its pipeline. The company's trajectory changed sharply in 2024, when it disclosed that it had fallen behind on required …

Nitish Kishor | 10 September 2026

YourWay Cannabis Brands (OTC: YOURF): A Snapshot of a Distressed Sub-Penny Stock

YourWay Cannabis Brands describes itself as a company that, through subsidiaries, manufactures, distributes and sells cannabis in the U.S. recreational and medicinal markets. It is a Canadian-incorporated entity, tied to Vancouver, British Columbia, with a U.S. operational presence associated with Phoenix, Arizona, and its …

Nitish Kishor | 10 September 2026

Sionna Therapeutics (NASDAQ: SION): Regrouping After a Cystic Fibrosis Setback

Sionna is a clinical-stage biopharmaceutical company developing medicines for cystic fibrosis (CF), a genetic disease driven by defects in the CFTR protein. The company went public onNasdaqin February 2025 and has pursued a differentiated approach aimed at stabilizing the NBD1 region of CFTR, alongside …

Nitish Kishor | 10 September 2026

CEL-SCI Corporation (NYSE American: CVM): Multikine's Phase 3 Progress in Focus

CEL-SCI is a clinical-stage immunotherapy company whose lead asset, Multikine (leukocyte interleukin injection), is being developed for certain head and neck cancers. In 2026 the company advanced on several fronts. On July 13, 2026, it launched a global, roughly 212-patient confirmatory registration Phase 3 …

Nitish Kishor | 10 September 2026

Artelo Biosciences (NASDAQ: ARTL): Progress Across a Three-Program Pipeline

Artelo Biosciences (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company built around the biology of lipids and the endocannabinoid system. Its portfolio spans oncology-supportive care, pain and metabolic health. In its second-quarter 2026 update, released in August, the company reiterated progress across three programs and …

Nitish Kishor | 10 September 2026

Procter & Gamble Director Receives Stock Award

A statement of changes in beneficial ownership filed on September 10, 2026 reports that Ashley McEvoy, a director of Procter & Gamble Co (NYSE:PG), received a grant of 207 shares of common stock on September 8, 2026.

Manish Choudhary | 10 September 2026
Support

Hi! How can we help you today?

Loading…